Parkinson’s illness, continually identified as PD, is the 2nd most frequent neurodegenerative dysfunction. The illness is characterised by a loss of dopamine-producing neurons in the substantia nigra, which is an verbalize of the brain chargeable for dash. Hashish, particularly CBD, has confirmed promise in treating just some of the symptoms of PD. In this video we can elaborate Parkinson’s illness and hashish, expose how hashish can reduction with PD, and doctor views on prescribing hashish.
This video became created by Demystifying Tablets students Simran Matharu, Mahek Minhas and Micaela McNulty in collaboration with the McMaster Demystifying Tablets Program
Copyright McMaster University 2021
For more files visit:
m
Time Stamps:
Introduction/What is Parkinson’s Illness? 00: 00 – 01: 23
What is Hashish? 01: 24 – 02: 34
How Can Hashish Lend a hand With Parkinson’s? 02: 35 – 05: 09
Doctor Perspectives 05: 10 – 07: 19
Conclusion 07: 20 – 07: 52
References:
Bega, D., Simuni, T., Okun, M. S., Chen, X., & Schmidt, P. (2016). Medicinal hashish for Parkinson’s illness: Practices, beliefs, and attitudes amongst services at national Parkinson Foundation centers of excellence. Circulation Disorders Scientific Educate, 4(1), 90-95.
Benner, E. J., Banerjee, R., Reynolds, A. D., Sherman, S., Pisarev, V. M., Tsiperson, V., Nemachek, C., Ciborowski, P., Przedborski, S., Mosley, R. L., & Gendelman, H. E. (2008). Nitrated alpha-synuclein immunity speeds up degeneration of nigral dopaminergic neurons. PloS one, 3(1), e1376.
Clapper, J. R., Mangieri, R. A., & Piomelli, D. (2009). The endocannabinoid machine as a target for the cure of hashish dependence. Neuropharmacology, 56, 235–243.
de Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson’s illness. The Lancet Neurology, 5(6), 525–535.
Edelstein, O. E., Wacht, O., Isralowitz, R., Reznik, A., & Bachner, Y. G. (2020). Beliefs and attitudes of graduate gerontology students about clinical marijuana utilize for Alzheimer’s and Parkinson’s illness. Complementary Therapies in Tablets, 52, 102418.
Gardiner, K. M., Singleton, J. A., Sheridan, J., Kyle, G. J., & Nissen, L. M. (2019). Health superior beliefs, files, and concerns surrounding medicinal hashish — A scientific overview. PLOS ONE, 14(5), e0216556.
Hauser, R. A., Rascol, O., Korczyn, A. D., Jon Stoessl, A., Watts, R. L., Poewe, W., De Deyn, P. P., & Lang, A. E. (2007). Ten-365 days educate-up of Parkinson’s illness sufferers randomized to preliminary therapy with ropinirole or levodopa. Circulation concerns: generous journal of the Circulation Disorder Society, 22(16), 2409–2417.
Jankovic, J. (2008). Parkinson’s illness: Scientific facets and prognosis. Journal of Neurology, Neurosurgery & Psychiatry, 79(4), 368–376.
Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L. E., Huang, X.-F., Liu, K., Arnold, J. C., & McGregor, I. S. (2011). Cannabidiol potentiates 9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics at some level of acute and persistent cure in adolescent rats. Psychopharmacology, 218(2), 443–457.
Lang, A. E., & Lozano, A. M. (1998). Parkinson’s Illness. Fresh England Journal of Tablets, 339(16), 1130–1143.
Laun, A. S., & Tune, Z. H. (2017). GPR3 and GPR6, unique molecular targets for cannabidiol. Biochemical and biophysical learn communications, 490(1), 17–21.
Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., Abbott, R. D., Savica, R., Van Den Eeden, S. K., Willis, A. W., & Tanner, C. (2018). Incidence of Parkinson’s illness across North The US. Npj Parkinson’s Illness, 4(1), 21.
Nutt J. G. (2000). Response to L-dopa in PD: the prolonged and the short of it. Neurology, 54(10), 1884–1885. 4
Oeckl, P., Hengerer, B., & Ferger, B. (2014). G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson’s illness. Experimental neurology, 257, 1–9. 0
Severe Spasticity. (2020).
Venderov, K., Rzicka, E., Vorsek, V., & Visnovsk, P. (2004). Gaze on hashish utilize in Parkinson’s illness: subjective enchancment of motor symptoms. Circulation concerns: generous journal of the Circulation Disorder Society, 19(9), 1102–1106. 1
Wang, M., Wang, Y.-H., Avula, B., Radwan, M. M., Wanas, A. S., Mehmedic, Z., van Antwerp, J., ElSohly, M. A., & Khan, I. A. (2017). Quantitative Resolution of Cannabinoids in Hashish and Hashish Merchandise The usage of Ultra-High-Efficiency Supercritical Fluid Chromatography and Diode Array/Mass Spectrometric Detection. Journal of Forensic Sciences, 62(3), 602–611. 1
